Objective. Prior studies have demonstrated an increased risk of cancer-associated scleroderma in patients with anti-RNA polymerase III (anti-RNAP III) autoantibodies as well as in patients who are triple-negative for anticentromere (anti-CENP), anti-topoisomerase I (antitopo I), and anti-RNAP III (also known as anti-POL) autoantibodies (referred to as CTP negative). In a recent study of 16 CTP-negative scleroderma patients with coincident cancer, 25% of the patients were found to have autoantibodies to RNPC-3, a member of the minor spliceosome complex. This investigation was undertaken to validate the relationship between anti-RNPC-3 antibodies and cancer and examine the associated clinical phenotype in a large sample of scleroderma patients.
Results. Of 318 patients with scleroderma and cancer, 70 (22.0%) were positive for anti-RNAP III, 54 (17.0%) were positive for anti-topo I, and 96 (30.2%) were positive for anti-CENP. Twelve patients (3.8% of the overall group or 12.2% of CTP-negative patients) were positive for anti-RNPC-3. Patients with anti-RNPC-3 had a short cancer-scleroderma interval (median 0.9 years). Relative to patients with anti-CENP, patients with anti-RNPC-3 and those with anti-RNAP III had a >4-fold increased risk of cancer within 2 years of scleroderma onset (for anti-RNPC-3-positive patients, odds ratio Conclusion. Anti-RNPC-3 autoantibodies, similar to anti-RNAP III autoantibodies, are associated with an increased risk of cancer at the onset of scleroderma. These data suggest the possibility of cancer-induced autoimmunity in this subset of patients with scleroderma.
Patients with systemic sclerosis (SSc; scleroderma) have an elevated risk of cancer compared with individuals in the general population (1) . Recent data have demonstrated that a close temporal relationship exists between the cancer diagnosis and the first clinical signs of scleroderma in a subset of patients (2, 3) . This clustering is most notable in patients with anti-RNA polymerase III (anti-RNAP III) autoantibodies (2) (3) (4) (5) (6) , who have a .5-fold increased risk of cancer within 2 years of scleroderma onset (3) . Findings from biologic studies have strongly suggested that paraneoplastic development of autoimmunity and scleroderma can occur in patients with anti-RNAP III autoantibodies. Genetic alterations (somatic mutations and/or loss of heterozygosity) of the POLR3A gene, which encodes for RNAP III, are also specifically identified in these patients' cancers, but not in the cancers in scleroderma patients with other autoantibodies (7) . Furthermore, these patients develop mutation-specific T cell immune responses and anti-RNAP III autoantibodies that react with both mutant and wild-type RNAP III proteins (7) . In aggregate, these studies suggest a model of cancerinduced autoimmunity in which autoantigen mutation in cancers may trigger the development of anti-tumor immune responses that then result in autoimmunity (8) .
In addition to patients with anti-RNAP III autoantibodies, there are other subsets of scleroderma patients who demonstrate a similar clustering of cancer diagnosis with the first clinical signs of scleroderma. This clustering is most notable among older patients developing scleroderma who are positive for antinuclear antibodies (ANAs) but negative for the 3 most common scleroderma autoantibodies observed in US cohorts (anticentromere [ (2, 3) . These individuals likely represent a heterogenous population of scleroderma patients in whom different autoantigens, both known and novel, are targeted.
We recently utilized phage-immunoprecipitation sequencing and PLATO (parallel analysis of in vitro translated open-reading frames) (9,10) to identify unique autoantibodies in CTP-negative scleroderma patients with a clustering of cancer diagnosis and scleroderma onset (11) . Specifically, 16 CTP-negative patients with scleroderma and cancer and with a short cancer-scleroderma interval (#5 years) were studied. Four (25%) of these 16 patients had autoantibodies to multiple adjacent peptides within RNA-binding protein-containing 3 (RNPC-3) (11), a 65-kd protein component of the minor spliceosome complex that participates in removal of U12-type introns from premessenger RNA (12, 13) . The minor spliceosome complex consists of several small nuclear RNAs (snRNAs) and multiple protein components, including the small nuclear ribonucleoproteins (snRNPs) 25, 35, and 48, programmed cell death protein 7, and the Sm proteins. RNPC-3 has 2 RNA recognition motifs, indicating that it likely contacts one of the snRNAs of the minor spliceosome. This anti-RNPC-3 specificity (also known as anti-U11/U12) has previously been described in patients with scleroderma, with a reported prevalence of 3.2% in the University of Pittsburgh scleroderma cohort (14) .
In this investigation, we sought to verify whether anti-RNPC-3 antibodies are associated with a short cancer-scleroderma interval in a large sample of patients with scleroderma and cancer, as this would provide additional evidence to support a model of cancer-induced autoimmunity. We also compared the prevalence of anti-RNPC-3 antibodies in CTP-negative patients with and those without cancer to determine whether anti-RNPC-3 autoantibodies are a marker of cancer risk overall. Similarly, we examined the clinical phenotype in these patients to identify whether any unique clinical characteristics could be a sign of an underlying cancer. In addition, we assayed anti-RNPC-3 antibodies in cancer patients without scleroderma to define whether anti-RNPC-3 antibodies are cancer biomarkers more broadly.
PATIENTS AND METHODS
Study population. Patients with scleroderma and an available serum sample were identified through the institutional review board-approved Johns Hopkins Scleroderma Center database. All patients were diagnosed as having scleroderma according to the American College of Rheumatology (ACR) 2013 classification criteria or the ACR 1980 classification criteria (15, 16) , or according to whether they had at least 3 of 5 features of the CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias). Demographic data, date of symptom onset, cutaneous SSc subtype (17) , organ-specific disease severity scores (18, 19) , smoking status, and cancer diagnosis (date of onset, site, histologic findings, and therapy) were ascertained in all patients at the first visit and longitudinally at 6-month intervals for relevant parameters. All clinically obtained pulmonary function test results and echocardiogram findings were recorded. The date of scleroderma onset was defined as the date of the first scleroderma symptom, categorized as either Raynaud's or non-Raynaud's phenomenon. The date of cancer diagnosis was obtained from pathology reports or medical record review when available, and was otherwise defined by patient report. The cancer-scleroderma interval was calculated as the difference between these 2 dates.
Cancer cohort and autoantibody status. We first examined our entire cohort of scleroderma patients with cancer and an available serum sample (n5 325). The serum sample obtained closest to the date of cancer diagnosis was studied for each participant. Autoantibodies against topo I, RNAP III, and CENP-A/B were assayed by enzyme-linked immunosorbent assays (ELISAs) using commercially available kits (Inova Diagnostics), and autoantibody levels of $40 units were defined as a true positive finding for our primary analyses. A sensitivity analysis was also performed, with antibody positivity redefined as a threshold of $20 units. Autoantibodies to RNPC-3 were assayed by immunoprecipitation of 35 S-methionine-labeled protein, generated by in vitro transcription and translation from complementary DNA encoding full-length RNPC-3 (purchased from Origene Technologies) as described previously (20) . Representative data from the immunoprecipitation assay to detect RNPC-3 antibodies are available upon request from the corresponding author. We restricted our primary analyses to patients who were positive for only 1 scleroderma autoantibody, as previously described (3). Of 325 patients with complete autoantibody data, only 7 patients were excluded from our analyses, because these patients were positive for multiple autoantibodies (largely overlapping with positivity for anti-CENP antibodies). Five of the 7 patients also had anti-RNPC-3 antibodies, of whom only 3 were moderately or strongly positive. Therefore, our study population consisted of 318 scleroderma patients with cancer.
Patients were subdivided into 5 autoantibody subgroups for analysis: patients positive for anti-RNAP III, anti-topo I, anti-CENP, or anti-RNPC-3 autoantibodies and patients negative for all 4 tested autoantibodies (anti-CENP, anti-topo I, anti-RNAP III, and anti-RNPC-3 [CTPR negative]). Demographic We also performed logistic regression analysis to examine whether anti-RNPC-3 and other autoantibodies were associated with an increased risk of cancer-associated scleroderma. Cancer-associated scleroderma was defined by a short cancerscleroderma interval (62 years), as previously described (3). The cancer-scleroderma interval was also examined graphically by generating scatterplots of age at scleroderma onset and age at cancer diagnosis for each autoantibody type.
Comparison cohort of CTP-negative scleroderma patients without cancer. Sixty CTP-negative scleroderma patients without cancer were also studied. The prevalence of anti-RNPC-3 positivity was compared between CTP-negative patients with cancer and those without cancer by chi-square test. We examined whether the clinical phenotype differed between anti-RNPC-3-positive patients with and those without cancer using the Wilcoxon-MannWhitney test or, where appropriate, the Fisher's exact test.
Comparison cohort of healthy controls and those with other disease states. Twenty-five healthy controls, 45 patients with pancreatic cancer, and 35 patients with lupus and cancer were also assayed for anti-RNPC-3 antibodies, in the same manner as described above.
Statistical analysis. All statistical analyses were performed using Stata version 13 (StataCorp). Two-sided P values less than 0.05 were considered statistically significant. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were determined.
RESULTS
Patients. In total, 318 scleroderma patients with cancer were analyzed ( Table 1 ). Seventy patients (22.0%) were positive for anti-RNAP III antibodies, 54 (17.0%) were positive for anti-topo I, 96 (30.2%) were positive for anti-CENP, and 12 (3.8%) were positive for anti-RNPC-3, leaving 86 patients (27.0%) in whom other autoantibody specificities are likely targeted (the CTPR-negative group). None of the controls (healthy subjects, patients with pancreatic cancer, or patients with lupus and cancer) had evidence of anti-RNPC-3 antibodies.
Association of anti-RNPC-3 autoantibodies with a short cancer-scleroderma interval and severe clinical phenotype. The cancer-scleroderma interval was significantly different across the 5 autoantibody subgroups. This finding persisted regardless of whether scleroderma onset was defined by the onset of Raynaud's phenomenon (P 5 0.0008), onset of the first non-Raynaud's symptom (P 5 0.0021), or onset of the first symptom (either Raynaud's or non-Raynaud's phenomenon; P 5 0.0001). Patients with anti-RNPC-3 autoantibodies had a short cancer-scleroderma interval (median 0.9 years), similar to that observed in patients with anti-RNAP III antibodies (median 1.0 years). This temporal clustering between cancer and scleroderma in patients positive for * The study population comprised 318 patients with systemic sclerosis (SSc) and cancer in the autoantibody subgroups of patients who were positive for anti-RNA polymerase III (anti-RNAP III; also known as anti-POL), anti-topoisomerase I (anti-topo I), anticentromere (anti-CENP), or anti-RNPC-3 autoantibodies and patients who were quadruple-negative for anti-CENP/anti-topo I/anti-RNAP III/anti-RNPC-3 (CTPR negative). IQR 5 interquartile range; non-RP 5 non-Raynaud's phenomenon; MRSS 5 modified Rodnan skin thickness score; RVSP 5 right ventricular systolic pressure; NT 5 not tested. † P values were determined using the Kruskal-Wallis test. ‡ The 4 remaining patients in the anti-CENP-positive group and 3 of the 4 in the CTPR-negative group met at least 3 of the 5 criteria for the CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias); 1 patient in the CTPR-negative group met the American College of Rheumatology (ACR) 1980 classification criteria for SSc. § Severe RP (pits, ulcers, gangrene) was defined as a Medsger severity score of $2 at baseline. Severe gastrointestinal (GI) disease was defined as a requirement for high-dose medications to treat gastroesophageal reflux disease, antibiotics needed for bacterial overgrowth, presence of malabsorption syndrome, episodes of pseudoobstruction, or a requirement for total parenteral nutrition. Severe lung disease was defined as a forced vital capacity (FVC) or diffusing capacity for carbon monoxide (DLCO) of ,70% of predicted. ¶ Myopathy was defined as a history of abnormal muscle enzyme levels or abnormal findings on electromyography, muscle biopsy, or magnetic resonance imaging. (Table 2 ). When we broadened our reference group to include patients with anti-CENP, patients with anti-topo I, and CTPR-negative patients, we found that patients with anti-RNPC-3 and those with anti-RNAP III had .3-fold increased odds of cancer within 2 years of scleroderma onset (for those with anti-RNPC-3, OR 3.57, 95% CI 1.01-12.6 [P 5 0.048]; for those with anti-RNAP III, OR 3.72, 95% CI 1.99-6.98 [P , 0.001]). These findings persisted in our sensitivity analyses in which autoantibody positivity was redefined at a lower cutoff of $20 units (data not shown).
ANTI-RNPC-3 IN CANCER-ASSOCIATED
All of the patients with anti-RNPC-3 autoantibodies were female, and the patients in this autoantibody subset were more likely to be African American (25% of patients) ( Table 1 ). There were statistically significant differences in age at scleroderma onset (P 5 0.0007) and disease duration at first visit (P 5 0.0001) across the autoantibody subgroups. Patients with anti-RNPC-3 antibodies and those with anti-RNAP III antibodies had a mean age at scleroderma onset of .50 years, and both subgroups had a shorter time to presentation for clinical evaluation than did the other autoantibody subgroups; this latter finding is likely attributable to the aggressive phenotype associated with these 2 autoantibodies (6, 14) . Patients with anti-RNPC-3 antibodies had less severe cutaneous and articular disease, as assessed by subtype distributions as well as by the modified Rodnan skin thickness score and the presence of tendon friction rubs. However, patients with anti-RNPC-3 antibodies had more severe restrictive lung disease at baseline, with a lower forced vital capacity and diffusing capacity for carbon monoxide and a higher Medsger severity score for lung disease compared with the other autoantibody subgroups. Anti-RNPC-3-positive patients also had associated pulmonary hypertension, which was defined as an elevated right ventricular systolic pressure (RVSP) on baseline echocardiography, although it is important to note the small size of the sample of patients with an estimated RVSP value available for this analysis. Anti-RNPC-3-positive patients had an associated myopathy (33.3% of patients) as well as severe gastrointestinal disease and severe Raynaud's phenomenon.
Given the small sample size, pairwise comparisons between the anti-RNPC-3 autoantibody subgroup and every other autoantibody subgroup were not performed because of the high likelihood that associations would be observed by chance alone. However, we compared anti-RNPC-3-positive and -negative patients and confirmed that anti-RNPC-3-positive patients had statistically significant associations, with a short cancer-scleroderma interval, severe restrictive lung disease consistent with interstitial lung disease, a higher baseline RVSP, severe Raynaud's phenomenon, and a history of myopathy (data not shown).
Although anti-RNPC-3 autoantibodies are not commercially available for clinical use, indirect immunofluorescence patterns on ANA testing may provide insights into autoantibody associations in CTP-negative Figure 1 . Relationship between age at cancer diagnosis and age at scleroderma onset. The red line in each graph denotes perfect agreement between age at cancer diagnosis and age at scleroderma onset (i.e., cancer-scleroderma interval of 0). CTPR-negative refers to the group of patients who were negative for all 4 autoantibodies tested (anticentromere [anti-CENP], anti-topoisomerase I, anti-RNA polymerase III [also known as anti-POL], and anti-RNPC-3). patients who might have this specificity. Of the 12 anti-RNPC-3-positive patients, 11 had available data on ANA patterns. Nine (81.8%) of the 11 patients had a speckled ANA pattern.
As some of the phenotypic features that are associated with anti-RNPC-3 autoantibodies are similar to that seen in patients with anti-U1 RNP autoantibodies, we also assessed whether anti-U1 RNP was present among these patients. No patient with anti-RNPC-3 autoantibodies was moderately to strongly positive for anti-U1 RNP on ELISA.
Patients with anti-RNPC-3 antibodies also had a worse prognosis, with a shorter time to death, as compared with patients in the other autoantibody subgroups (median survival 9.0 years in anti-RNPC-3-positive patients versus .20 years in all other antibody subgroups; P , 0.0001 by log-rank test) (details available upon request from the corresponding author). While statistical comparisons of all tumor types were not possible with our small sample size, it is noteworthy that most malignancies in the anti-RNPC-3-positive group (66.7% of patients) were gynecologic tumors in women, with 50% of these patients having breast cancer (P 5 0.075 for comparison across antibody subgroups).
Prevalence of anti-RNPC-3 autoantibodies and clinical phenotype of anti-RNPC-3-positive patients does not differ by cancer status. Among the CTP-negative scleroderma patients, there were no significant differences in the prevalence of anti-RNPC-3 antibodies by cancer status (12 [12. 2%] of 98 patients with cancer were anti-RNPC-3 positive, compared with 8 [13.3%] of 60 patients without cancer; P 5 0.842). We examined whether unique phenotypic features could identify the subset of patients with an underlying cancer among anti-RNPC-3-positive patients, as clinical differences could aid in risk stratification for cancer screening. Our sample size was limited to 12 anti-RNPC-3-positive patients with cancer and 8 anti-RNPC-3-positive patients without cancer. There were no statistically significant differences in age at scleroderma onset, age at cancer diagnosis, disease duration at first visit, sex, race, cutaneous subtype, organ-specific severity scores, baseline pulmonary function, history of myopathy, or history of articular disease (data not shown).
DISCUSSION
This investigation found that scleroderma patients with anti-RNPC-3 autoantibodies have a short cancerscleroderma interval (median 0.9 years), similar to that observed in patients with anti-RNAP III antibodies (median 1.0 years). Relative to patients with anti-CENP autoantibodies, patients with anti-RNPC-3 antibodies and those with anti-RNAP III antibodies had a .4-fold increased risk of cancer occuring within 2 years of scleroderma onset. The presence of anti-RNPC-3 autoantibodies did not signify an increased risk of cancer overall, but did identify a subset of patients who have an increased risk of cancer at the time of the first clinical manifestations of scleroderma. The temporal association between cancer and scleroderma in patients with anti-RNPC-3 antibodies is very similar to that observed in patients with anti-RNAP III antibodies, and strongly suggests that additional, serologically defined subsets of scleroderma patients may have cancer-induced autoimmunity (2, 3, 7, 8) . Although the mechanistic relationship between cancer and scleroderma among patients with anti-RNPC-3 antibodies is unknown, these data support the idea that cancer might initiate scleroderma-specific immune responses and also provide a rationale for targeted malignancy screening at the time of scleroderma onset.
In our study of scleroderma patients with cancer, patients with anti-RNPC-3 were more likely to be African American and to have severe interstitial lung disease, gastrointestinal disease, and Raynaud's phenomenon. Even among a cohort of patients with a history of cancer, patients with anti-RNPC-3 had a faster time to death from scleroderma onset than did patients without anti-RNPC-3, which may be consistent with the aggressive phenotype of these patients. Overall, our findings related to the clinical phenotype and prevalence estimates (3.8% in the Johns Hopkins cohort and 3.2% in the University of Pittsburgh cohort) are similar to those previously described for anti-U11/U12 antibodies in the University of Pittsburgh scleroderma cohort (14) . Our data suggest that patients with anti-RNPC-3 may be more likely to have a myopathy, which has not been described before; further study is required to validate this finding in a larger cohort.
Recognizing that the prevalence of anti-RNPC-3 antibodies was low in our cohort, we were unable to identify any significant clinical phenotypic differences between anti-RNPC-3-positive patients with cancer compared with those without cancer. Anti-RNPC-3 autoantibodies were unique to scleroderma and were not found in cancer patients without scleroderma, demonstrating that anti-RNPC-3 antibodies are not cancer biomarkers in nonscleroderma populations.
As in patients with anti-RNAP III autoantibodies, these data support the practice of careful cancer screening at the onset of scleroderma in patients with anti-RNPC-3 autoantibodies. As we begin to identify more subsets of patients with possible cancer-associated scleroderma, it will be critical to consider evidence-based approaches to define the optimal cancer screening algorithm in these patients to maximize cancer dectection while minimizing the risks associated with false positive testing. The approach to cancer screening in scleroderma may vary by autoantibody subtype. In our small sample of anti-RNPC-3-positive patients with cancer, 50% of the malignancies were breast cancers, suggesting that mammography is important. The remaining cancers seen in our anti-RNPC-3-positive patients were gynecologic, hematologic, and skin in origin.
Our study was conducted in the largest cohort of well-characterized patients with scleroderma and cancer to date, but it was limited by the small sample size of patients with anti-RNPC-3 autoantibodies. While we observed statistically significant differences, it is important to note that we could not perform pairwise comparisons between each pair of autoantibody subgroups, due to our sample size. In addition, our control group was restricted to scleroderma patients who were CTP negative and without cancer. Finally, although our data demonstrating a clustering of cancer diagnosis with scleroderma onset suggest a paraneoplastic mechanism of scleroderma onset, similar to that in patients with anti-RNAP III autoantibodies, this investigation did not examine whether genetic or posttranslational alterations of RNPC-3 are present in the cancer tissue of these patients.
In conclusion, anti-RNPC-3 autoantibodies are associated with an increased risk of cancer at scleroderma onset, similar to the findings in patients with anti-RNAP III autoantibodies. These data suggest the possibility of cancer-induced autoimmunity in this subset of patients with scleroderma, and biologic studies of autoantigen alterations in tissue samples from anti-RNPC-3-positive patients with cancer remain an important priority. Awareness of the association between anti-RNPC-3 antibodies and cancer in patients with scleroderma provides an opportunity for early cancer detection and intervention, which may improve overall outcomes.
